FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211552810> ?p ?o ?g. }

• W3211552810 endingPage "3785" @default.
• W3211552810 startingPage "3785" @default.
• W3211552810 abstract "Abstract Background: Anti-CD38 monoclonal antibodies have become a standard treatment option for patients with either relapsed/refractory (RR) or newly diagnosed multiple myeloma (MM). There are two approved drugs in this class, daratumumab and isatuximab. These agents have become a mainstay of myeloma treatment being used in a variety of combination approaches. Although they are widely used, very little has been reported regarding the benefit they provide if they are used again in subsequent lines of therapy among patients that have already been treated with prior anti-CD38 containing regimens. Methods: MM patients that were treated at the Berenson Cancer Center and previously received either daratumumab or isatuximab and were treated with another anti-CD38-containing combination were retrospectively analyzed. Response to each anti-CD38 regimen was evaluated for responses according to the International Myeloma Working Group (IMWG) criteria. We used Kaplan-Meier curves to determine progression free survival (PFS) and overall survival (OS). Results: There were 49 patients identified as having received &gt; 2 anti-CD38 containing regimens. Among these patients, 40, 1, and 8 received only daratumumab, only isatuximab, or a combination of both anti-CD38 regimens. 17, 19, 8, and 41 received an IMiD, PI, a combination of both, or other combinations. Overall, the median PFS was 3.9, 3.2, 2.6, 1.9, and 1.5 months for the first (n=49), second (n=49), third (n=23), fourth (n=15), and fifth (n=8) exposures, respectively. For their first anti-CD38 containing regimen (n=49), the clinical benefit rate (CBR) and overall response rate (ORR) were 44.9% and 38.8%, respectively (7.7% MR, 34.7% PR, and 4.1% CR), and 36.7% showed SD. During their second exposure (n=49), the CBR and ORR were 42.9% and 40.8%, respectively (2.0% MR, 36.7% PR, 12.0% VGPR, and 2.0% CR) and 36.7% showed SD. The PFS among patients who were exposed to a second regimen and discontinued therapy without disease progression to their first anti-CD38 containing regimen was 5.9 months compared with only 3.0 months for those who progressed during their first regimen. OS from the start of anti-CD38 treatment was a median of 36.5 months (range, 1.8-56.5). OS was longer among patients who did not progress on first exposure with a median of 26.2 months (range, 1.8-56.5) compared to patients who progressed during their first regimen (median not yet reached; range, 7.6-54.5). PFS among patients treated with a proteasome inhibitor (PI)-containing combination in their first exposure was 8.7 months versus 4.5 months among patients who were treated with an immunomodulatory agent (IMiD)-containing treatment. Additionally, the PFS among patients treated with a PI versus an IMiD with their second exposure to an anti-CD38 containing regimen was 5.9 and 2.8 months, respectively. Conclusions: Our retrospective study suggests that RRMM patients who are retreated with another anti-CD38 containing regimens can continue to respond after multiple exposures to this drug class. The ORR differs little during the first two exposures to these agents for RRMM patients. To our knowledge, this study provides support for retreatment of RRMM patients with anti-CD38 containing regimens. Additional studies are planned to further investigate this patient population. Disclosures Vescio: Janssen: Speakers Bureau; Karyopharm: Speakers Bureau; GlaxoSnithKlein: Speakers Bureau; Amgen: Speakers Bureau." @default.
• W3211552810 created "2021-11-22" @default.
• W3211552810 creator A5021554856 @default.
• W3211552810 creator A5031528335 @default.
• W3211552810 creator A5031848378 @default.
• W3211552810 creator A5033231097 @default.
• W3211552810 creator A5037540065 @default.
• W3211552810 creator A5040835019 @default.
• W3211552810 creator A5045444077 @default.
• W3211552810 creator A5051487070 @default.
• W3211552810 creator A5052345783 @default.
• W3211552810 creator A5084603634 @default.
• W3211552810 date "2021-11-05" @default.
• W3211552810 modified "2023-09-28" @default.
• W3211552810 title "Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab" @default.
• W3211552810 doi "https://doi.org/10.1182/blood-2021-154350" @default.
• W3211552810 hasPublicationYear "2021" @default.
• W3211552810 type Work @default.
• W3211552810 sameAs 3211552810 @default.
• W3211552810 citedByCount "1" @default.
• W3211552810 countsByYear W32115528102022 @default.
• W3211552810 crossrefType "journal-article" @default.
• W3211552810 hasAuthorship W3211552810A5021554856 @default.
• W3211552810 hasAuthorship W3211552810A5031528335 @default.
• W3211552810 hasAuthorship W3211552810A5031848378 @default.
• W3211552810 hasAuthorship W3211552810A5033231097 @default.
• W3211552810 hasAuthorship W3211552810A5037540065 @default.
• W3211552810 hasAuthorship W3211552810A5040835019 @default.
• W3211552810 hasAuthorship W3211552810A5045444077 @default.
• W3211552810 hasAuthorship W3211552810A5051487070 @default.
• W3211552810 hasAuthorship W3211552810A5052345783 @default.
• W3211552810 hasAuthorship W3211552810A5084603634 @default.
• W3211552810 hasBestOaLocation W32115528101 @default.
• W3211552810 hasConcept C10205521 @default.
• W3211552810 hasConcept C126322002 @default.
• W3211552810 hasConcept C143998085 @default.
• W3211552810 hasConcept C159912055 @default.
• W3211552810 hasConcept C2776063141 @default.
• W3211552810 hasConcept C2776364478 @default.
• W3211552810 hasConcept C2781119759 @default.
• W3211552810 hasConcept C2781413609 @default.
• W3211552810 hasConcept C28328180 @default.
• W3211552810 hasConcept C54355233 @default.
• W3211552810 hasConcept C71924100 @default.
• W3211552810 hasConcept C86803240 @default.
• W3211552810 hasConceptScore W3211552810C10205521 @default.
• W3211552810 hasConceptScore W3211552810C126322002 @default.
• W3211552810 hasConceptScore W3211552810C143998085 @default.
• W3211552810 hasConceptScore W3211552810C159912055 @default.
• W3211552810 hasConceptScore W3211552810C2776063141 @default.
• W3211552810 hasConceptScore W3211552810C2776364478 @default.
• W3211552810 hasConceptScore W3211552810C2781119759 @default.
• W3211552810 hasConceptScore W3211552810C2781413609 @default.
• W3211552810 hasConceptScore W3211552810C28328180 @default.
• W3211552810 hasConceptScore W3211552810C54355233 @default.
• W3211552810 hasConceptScore W3211552810C71924100 @default.
• W3211552810 hasConceptScore W3211552810C86803240 @default.
• W3211552810 hasIssue "Supplement 1" @default.
• W3211552810 hasLocation W32115528101 @default.
• W3211552810 hasOpenAccess W3211552810 @default.
• W3211552810 hasPrimaryLocation W32115528101 @default.
• W3211552810 hasRelatedWork W1197848312 @default.
• W3211552810 hasRelatedWork W2010232494 @default.
• W3211552810 hasRelatedWork W2018962392 @default.
• W3211552810 hasRelatedWork W2968266202 @default.
• W3211552810 hasRelatedWork W2980429921 @default.
• W3211552810 hasRelatedWork W3046891979 @default.
• W3211552810 hasRelatedWork W3121407702 @default.
• W3211552810 hasRelatedWork W3134875278 @default.
• W3211552810 hasRelatedWork W4229333964 @default.
• W3211552810 hasRelatedWork W4233315676 @default.
• W3211552810 hasVolume "138" @default.
• W3211552810 isParatext "false" @default.
• W3211552810 isRetracted "false" @default.
• W3211552810 magId "3211552810" @default.
• W3211552810 workType "article" @default.